Interaction of clarithromycin with cyclosporine in cats: Pharmacokinetic study and case report

Journal of Feline Medicine and Surgery

Volumn 14, Issue 4, 2012, Pages 257-261

  Katayama, Masaaki ^a   Nishijima, Noriko ^a   Okamura, Yasuhiko ^a   Katayama, Rieko ^a   Yamashita, Testuro ^a   Kamishina, Hiroaki ^b   Uzuka, Yuji ^a  

^a IWATE UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FELIDAE;

CLARITHROMYCIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; CAT; CAT DISEASE; CHRONIC KIDNEY FAILURE; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG INTERACTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE;

ANIMALS; CAT DISEASES; CATS; CLARITHROMYCIN; CROSS-OVER STUDIES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE;

EID: 84864072379     PISSN: 1098612X     EISSN: 15322750     Source Type: Journal    
DOI: 10.1177/1098612X11435612     Document Type: Article

References (28)

1. Katayama M and McAnulty J. Renal transplantation in cats: patient selection and preoperative management. Compend Cont Edu Pract Vet 2002; 24: 868-73, 874-882.
2. Guaguere E, Steffan J and Olivry T. Cyclosporin A: a new drug in the field of canine dermatology. Vet Dermatol 2004; 15: 61-74.
3. Mathews KA, Ayres SA, Tano CA, et al. Cyclosporin treatment of perianal fistulas in dogs. Can Vet J 1997; 38: 39-41.
4. Morgan RV and Abrams KL. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc 1991; 199: 1043-1046.
5. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 201-214.
6. Whalen RD, Tata PN, Burckart GJ, et al. Species differences in the hepatic and intestinal metabolism of cyclosporine. Xenobiotica 1999; 29: 3-9.
7. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-1490.
8. McAnulty JF and Lensmeyer GL. The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. Vet Surg 1999; 28: 448-455.
9. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123-128.
10. Spicer ST, Liddle C, Chapman JR, et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997; 43: 194-196.
11. Pinto AG, Wang YH, Chalasani N, et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 2005; 77: 178-188.
12. Hughes J and Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 2010; 113: 315-324.
13. Knower MT, Labella-Walker K, McFadden PM, et al. Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients. South Med J 2000; 93: 108792.
14. Gregory C and Bernsteen L. Organ transplantation in clinical veterinary practice. In: Slatter D (ed). Textbook of small animal surgery. 3rd ed. Philadelphia, PA: Saunders, 2003, pp 112-136.
15. Roudebush P, Polzin DJ, Ross SJ, et al. Therapies for feline chronic kidney disease. What is the evidence? J Feline Med Surg 2009; 11: 195-210.
16. Sadaba B, Lopez de Ocariz A, Azanza JR, et al. Concurrent clarithromycin and cyclosporin A treatment. J Antimicrob Chemother 1998; 42: 393-395.
17. Murray M. Drug-mediated inactivation of cytochrome P450. Clin Exp Pharmacol Physiol 1997; 24: 465-470.
18. Pessayre D, Larrey D, Vitaux J, et al. Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem Pharmacol 1982; 31: 1699-1704.
19. Ohmori S, Ishii I, Kuriya S, et al. Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab Dispos 1993; 21: 358-363.
20. Katayama M, Katayama R and Kamishina H. Effects of multiple oral dosing of itraconazole on the pharmacokinetics of cyclosporine in cats. J Feline Med Surg 2010; 12: 512-514.
21. Culic O, Erakovic V and Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209-229.
22. Morikawa K, Oseko F, Morikawa S, et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1994; 38: 2643-2647.
23. Elsner L, Wayne J, O'Brien CR, et al. Localised Mycobacterium ulcerans infection in a cat in Australia. J Feline Med Surg 2008; 10: 407-412.
24. Khoshnegah J, Jamshidi S, Mohammadi M, et al. The efficacy and safety of long-term Helicobacter species quadruple therapy in asymptomatic cats with naturally acquired infection. J Feline Med Surg 2011; 13: 88-93.
25. Courtin F, Huerre M, Fyfe J, et al. A case of feline leprosy caused by Mycobacterium lepraemurium originating from the island of Kythira (Greece): diagnosis and treatment. J Feline Med Surg 2007; 9: 238-241.
26. Kadar E, Sykes JE, Kass PH, et al. Evaluation of the prevalence of infections in cats after renal transplantation: 169 cases (1987-2003). J Am Vet Med Assoc 2005; 227: 948-953.
27. Mishina M, Watanabe T, Maeda H, et al. Renal transplantation in cats with chronic renal failure. J Vet Med Sci 1996; 58: 655-658.
28. Schmiedt CW, Holzman G, Schwarz T, et al. Survival, complications, and analysis of risk factors after renal transplantation in cats. Vet Surg 2008; 37: 683-695.